




30th

Annual Conference of
Italian Association of Cell Cultures (AICC)

NOVEMBER 27-28, 2017 - MILAN, ITALY



TUMOR-IMMUNE CELL INTERFACE IN SOLID AND HEMATOLOGICAL MALIGNANCIES

Reprogramming the immune
microenvironment toward better
outcome and response to therapy



Fondazione IRCCS
Istituto Nazionale dei Tumori
Via Venezian 1, Milan

Aula Magna
"Gianni Bonadonna"

PRESENTATION OF THE CONFERENCE

The 30th Conference of Italian Association of Cell Culture (AICC) will take place in Milan on November 27-28, 2017 at the Fondazione IRCCS Istituto Nazionale dei Tumori, the Cancer Centre cradle of Italian oncology.

Tumors comprise not only cancerous but also normal cells that, as stromal components, actively participate to tumor progression and metastatization. Among them, tumor-driven immune cells are potent allies in sustaining tumor growth.

The conference will focus on the role of immune cells in tumor development and progression and on the possible strategies to re-educate tumor-promoting leukocytes toward anti-tumor functions.

The meeting is organized in two days with 5 thematic sessions, national and international speakers, leaders in their scientific fields, an opening and a closing lecture and selected abstract oral presentations. Sessions will cover different topics: immunosuppression, immunotherapy, tumor microenvironment in hematological tumors, tumor metabolism and new tools for modeling tumor-stroma interaction.

New insights into basic, translational and clinical research will be discussed, to provide an opportunity of interaction and collaboration among participants.

We hope the Conference will be of your interest and look forward to meeting you in Milan.

Claudia Chiodoni

Mario P. Colombo



AICC SCIENTIFIC BOARD

President

Katia Scotlandi, IRCCS Rizzoli Orthopaedic Institute, Bologna

VicePresident and Treasurer

Michele Caraglia, Università della Campania "L. Vanvitelli"

Board of Directors and Secretary

Stefania Meschini, Istituto Superiore di Sanità, Rome

Board of Directors

Francesca Zazzeroni, Università degli Studi dell'Aquila

Massimo Donadelli, Università di Verona

Maria Teresa Di Martino, Università "Magna Graecia", Catanzaro

Claudia Chiodoni, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

Past President

Carlo Leonetti, Regina Elena National Cancer Institute, Rome

SCIENTIFIC COMMITTEE

Scientific Coordinators

Fondazione IRCCS Istituto Nazionale dei Tumori

Claudia Chiodoni and **Mario Paolo Colombo**

Local Scientific Committee

Fondazione IRCCS Istituto Nazionale dei Tumori

Maria Chiara Anania, **Alessandra Cataldo**,

Orazio Fortunato, **Veronica Huber**, **Elena Jachetti**,

Alessandro Satta, **Michele Sommariva**, **Elena Tassi**

AICC SECRETARIAT

Istituto Superiore di Sanità

Stefania Meschini - stefania.meschini@iss.it

Evelin Pellegrini - evelin.pellegrini@guest.iss.it

ORGANIZING SECRETARIAT

Fondazione IRCCS Istituto Nazionale dei Tumori

Phone: +39 02 23902212

Ester Grande - ester.grande@istitutotumori.mi.it

Claudia Chiodoni - claudia.chiodoni@istitutotumori.mi.it

SPEAKERS

Andrea Anichini, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

Chiara Arrigoni, Istituto Ortopedico Galeazzi, Milan

Alessandra Carè, Istituto Superiore di Sanità, Rome

Serena Danti, Università di Pisa

Silvia Deaglio, Università di Torino

Michele De Palma, EPFL, ISREC, Lausanne, Switzerland

Marina Garassino, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

Stefano Indraccolo, Istituto Oncologico Veneto, Padua

Anna Mondino, San Raffaele Scientific Institute, Milan

Alessio Nencioni, Università degli Studi di Genova, San Martino IST, Genoa

Silvia Piconese, Università La Sapienza, Rome

Licia Rivoltini, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

Davide Rossi, Institute of Oncology Research and Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

Sabina Sangaletti, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

Jürg Schwaller, University of Basel, Switzerland

Antonio Sica, Università del Piemonte Orientale, Novara

Claudio Tripodo, Università di Palermo, School of Medicine

GENERAL INFORMATION

CONFERENCE VENUE

Aula Magna Gianni Bonadonna

Fondazione IRCCS Istituto Nazionale dei Tumori

Via Venezian 1, 20133, Milan

www.istitutotumori.mi.it

REGISTRATION FEES (VAT included)

AICC Members	€ 200,00
GISM Members	€ 200,00
Non-Members	€ 250,00 (€ 200,00+50,00 membership fee)
Ph.D. Students, Students	€ 50,00 (membership fee)
One-day registration	€ 150,00 (€ 100,00+50,00 membership fee)
On site	€ 280,00 (€ 230,00+50,00 membership fee)

The registration fee includes:

- Attendance at the 30th Annual Conference of Italian Association of Cell Cultures (AICC)
- Attendance Certificate
- Conference Kit, Coffee Breaks, Lunches

SOCIAL EVENT

Monday, November 27th 2017, Social dinner.

Social dinner contribution fee € 35,00

Reservation for social dinner will be accepted until November 8th 2017.

BEST POSTER and ORAL PRESENTATION AWARDS

During the conference AICC will award poster prizes for researchers under 35 years of age.

Two “Guido Berlucchi Foundation Best Poster Prize” will be available for researchers under 35 of any nationality, for oncology research implemented in an Italian laboratory. Each prize is of 500 euros.

One prize (500 euros) for the best poster on tumor immunotherapy will be awarded, for researchers under 35, from the *Journal of Experimental & Clinical Cancer Research*.

One “Guido Berlucchi Foundation Best Oral Presentation Prize” will be available for researchers under 40 of any nationality, for oncology research implemented in an Italian laboratory. The prize is of 500 euros, plus a bonus to be used by the winner for the attendance to the 2018 event of any Scientific Society in the oncology.

LANGUAGE

The official language of the Conference is English.



30th

Annual Conference of
Italian Association of Cell Cultures (AICC)

SCIENTIFIC PROGRAMME

TUMOR-IMMUNE CELL INTERFACE IN SOLID AND HEMATOLOGICAL MALIGNANCIES

November 27-28, 2017 - Milan, Italy

SCIENTIFIC PROGRAMME

Monday, November 27th 2017

09.30 *Registration and poster set-up*

10.30 OPENING CEREMONY
Greetings from the Authorities
Greetings from AICC President

11.30 OPENING LECTURE
Reprogramming the tumor immune microenvironment.
Michele De Palma (EPFL, ISREC, Lausanne, Switzerland)

12.30 *Lunch and poster viewing*

SESSION 1

3D CULTURES AND MICROFLUIDICS:
NEW TOOLS FOR MODELING TUMOR-STROMA INTERACTIONS
Chairs: **Francesca Zazzeroni** and **Orazio Fortunato**

13.40 Microfluidic and mesoscale vascularized 3D human models to study cancer metastases: dissection of the combined effects of neutrophils and platelets.
Chiara Arrighi (IRCCS Istituto Ortopedico Galeazzi, Milan)

14.10 Effect of scaffold chemistry and porosity on 3D organization of different carcinoma cells.
Serena Danti (Università di Pisa)

14.40 *Selected talks*
A 3D stomal-based microenvironment to assess drug efficacy in chronic lymphocytic leukaemia. **39**
Edoardo Visentin (San Raffaele Scientific Institute, Milan)

Impact of cancer stem cell-associated macrophages on cholangiocarcinoma onset and progression. **11**
Margherita Correnti (Humanitas Clinical and Research Center, Milan)

Microfluidic chip technology as an innovative tool to investigate cancer and immune cells crosstalk for chemo- and immunotherapy. **22**
Fabrizio Mattei (Istituto Superiore di Sanità, Rome)

15.10 "Materials & Methods" talks
Standardization and reproducibility in flow cytometry.
Giulio Bassi (*Miltenyi Biotec*)

How HTG Molecular Diagnostics Gene Expression Based
Molecular Profiling Could Help Improve Cancer Diagnostics.
Jean Claude Gerard (*HTG*)

15.50 Coffee break

SESSION 2

TUMOR METABOLISM

Chairs: **Massimo Donadelli** and **Michele Sommariva**

16.20 Anti-angiogenic therapy triggers metabolic rewiring in tumors.
Stefano Indraccolo (*Istituto Oncologico Veneto, Padua*)

16.50 Fasting and fasting-mimicking diets as a means to increase
efficacy and tolerability of anticancer treatments.
Alessio Nencioni (*Università degli Studi di Genova,
San Martino IST, Genoa*)

17.20 SCD5-based oleic acid induction or its direct supplementation
triggers antitumor activities.
Alessandra Carè (*Istituto Superiore di Sanità, Rome*)

17.50 Selected talks
pH regulatory inhibitors as therapeutic strategy in hepatocellular
carcinoma. **38**
Alessandra Tuccitto (*Fondazione IRCCS Ist. Nazionale dei Tumori, Milan*)

PD1+ Tumor infiltrating T lymphocytes accumulate in highly metabolic
tumors in pancreatic adenocarcinoma. **8**
Giovanni Castino (*Humanitas Clinical and Research Center, Milan*)

Label-free visualization of the metabolic switch induced by iron
depletion in breast cancer cells. **13**
Francesco Crisafi (*Politecnico di Milano, Milan*)

18.30 AICC Member Meeting

20.30 Social Dinner

SCIENTIFIC PROGRAMME

Tuesday, November 28th 2017

SESSION 3

TUMOR MICROENVIRONMENT IN
HEMATOLOGICAL MALIGNANCIES

Chairs: **Maria Teresa Di Martino** and **Elena Jachetti**

- 08.30** Chronic Lymphocytic Leukemia niche: a place of dangerous liaisons.
Silvia Deaglio (*Universita di Torino*)
- 09.00** Lymphoma phenotype specification by matricellular protein proficiency.
Claudio Tripodo (*Universita di Palermo, School of Medicine*)
- 09.30** Lymphoma genotyping on the liquid biopsy.
Davide Rossi (*Institute of Oncology Research and Oncology Institute of Southern Switzerland, Bellinzona, Switzerland*)
- 10.00** *Selected talks*
- NKG2A as a therapeutic target to improve NK cells alloreactivity to cure haploidentical hematopoietic stem cell transplanted patients. **40**
Elisa Zaghi (*Humanitas Clinical and Research Center, Milan*)
- P2X7 receptor splice variants as potential biomarkers and therapeutic targets in AML. **30**
Anna Pegoraro (*University of Ferrara*)
- 10.30** *Coffee break*

SESSION 4

IMMUNOTHERAPY AND TREATMENT RESISTANCE

Chairs: **Stefania Meschini** and **Veronica Huber**

- 11.00** Adoptive T cell therapy for solid tumors:
dual Tumor/Tumor-stroma targeting approaches.
Anna Mondino (*San Raffaele Scientific Institute, Milan*)
- 11.30** Resistance to immune checkpoint blockade in melanoma:
analysis at tumor site.
Andrea Anichini (*Fondazione IRCCS Ist. Nazionale dei Tumori, Milan*)
- 12.00** Overcoming resistances in immunotherapy.
Marina Garassino (*Fondazione IRCCS Ist. Nazionale dei Tumori, Milan*)

12.30 *Selected talks*

Novel Therapies in Non-Small Cell Lung Cancer harbouring ALK-rearrangements. **27**

Ines Mota (*Centro di Ricerca Medica Sperimentale, Turin*)

ABCA1 bridges lipid metabolism and anti-tumor immune system activity. **21**

Chiara Riganti (*Università degli Studi di Torino*)

IL-33 exerts antitumoral activities against melanoma through activation of eosinophils. **23**

Giovanna Schiavoni (*Istituto Superiore di Sanità, Rome*)

13.00 *Lunch and Poster Viewing*

SESSION 5

TUMOR-ASSOCIATED IMMUNOSUPPRESSION

Chairs: **Michele Caraglia** and **Elena Tassi**

14.00 Exploiting myeloid cells as prognostic biomarker and therapeutic target in cancer patients.

Licia Rivoltini (*Fondazione IRCCS Istituto Nazionale dei Tumori, Milan*)

14.30 Reprogramming of myeloid cell functions in cancer development.

Antonio Sica (*Università del Piemonte Orientale, Novara*)

15.00 Extracellular Matrix Regulation of Myeloid Cell Activity in the Tumor Microenvironment.

Sabina Sangaletti (*Fondazione IRCCS Ist. Nazionale dei Tumori, Milan*)

15.30 Immunometabolic checkpoints of regulatory T cell dynamics in cancer.

Silvia Piconese (*Università La Sapienza, Rome*)

16.00 *Selected talks*

Therapeutic potential of BoxA in malignant mesothelioma. **26**

Rosanna Mezzapelle (*San Raffaele Hospital, Milan*)

The VEGFC/VEGFR3 pathway drives immune tolerance in Colorectal Cancer. **35**

Federica Rubbino (*Humanitas Clinical and Research Center, Milan*)

Bimodal crosstalk between iNKT cells and Tumor-Associated Macrophages locally controls prostate cancer progression. **12**
Filippo Cortesi (*San Raffaele Scientific Institute, Milan*)

16.30 **AWARDS CEREMONY**

Best poster and oral presentation awards from
Fondazione Guido Berlucchi and AICC
Chairs: **Katia Scotlandi** and **Carlo Leonetti**

16.45 **CLOSING LECTURE**

Modeling the cellular origin of acute myeloid leukemia
in transgenic mice.
Jürg Schwaller (*University of Basel, Switzerland*)

17.30 *Closing Remarks*